We can rebuild him; we have the technology--but Americans question if we should in a new survey designed to assess attitudes to modern biotechnology advances.

Kite Pharma has always been focused on engineering a patient’s own T cells to treat their cancer. But now, it’s in-licensed tech to create off-the-shelf T-cell…

Bristol-Myers Squibb is really racking up the cancer pacts as today it pens another deal for its PD-1 checkpoint inhibitor Opdivo (nivolumab)--this time to be…

AstraZeneca and partner Moderna Therapeutics are heading to the lab for the first time together with their experimental cardiometabolic drug AZD8601.

Tobira Therapeutics fell by about half in premarket trading on news that its Phase IIb trial to treat nonalcoholic steatohepatitis (NASH) failed to meet the…

As the world’s top researchers working in Alzheimer’s disease descend into Toronto for the AAIC this week, all will be coming with a continued show of hope--…

California upstart Tricida has raised its highest level of cash to date with a $55 million Series C funding round backed by major biotech VC players.

Bristol-Myers Squibb will team up with AbbVie to run an early-stage lung cancer study combining BMS’ marketed checkpoint inhibitors with AbbVie’s experimental…